NCT04893031 is a clinical trial of Tocilizumab in Tocilizumab, sponsored by Karadeniz Technical University.

Who is sponsoring NCT04893031?

NCT04893031 is sponsored by Karadeniz Technical University.

What drugs are being tested in NCT04893031?

Interventions in NCT04893031: Tocilizumab.

What condition does NCT04893031 study?

NCT04893031 studies Tocilizumab, COVID-19, Critical Care, Mortality.

Is NCT04893031 still recruiting?

NCT04893031 is currently completed. Last updated 20 May 2021.

Last reviewed 2021-05-20 · How we verify

NCT04893031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Completed Last updated 20 May 2021

What this trial tests

trial testing Tocilizumab in Tocilizumab in 213 participants. Completed in 1 April 2021.

Timeline

1 March 2020

Primary endpoint
1 March 2021

1 April 2021

Quick facts

Lead sponsor	Karadeniz Technical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	213
Start date	1 March 2020
Primary completion	1 March 2021
Estimated completion	1 April 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →

Conditions studied

Tocilizumab — all drugs for Tocilizumab →
COVID-19 — all drugs for COVID-19 →
Critical Care — all drugs for Critical Care →
Mortality — all drugs for Mortality →

Sponsor

Karadeniz Technical University

Who can join

18 and older, any sex, with Tocilizumab or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although its safety and efficacy in the COVID-19 patient population are still unclear, tocilizumab is one of treatment. Tocilizumab is a U.S. Food and Drug Administration approved IL-6 receptor antagonist widely used to treat CRS secondary to the chimeric antigen receptor T cell. In this study the investigators will evaluate the efficacy of Tocilizumab, an IL-6 antagonist administered in the early period in intensive care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation is predominant, but who do not support mechanical ventilation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.
Ng WH, Tang PCH, Mahalingam S, Liu X. · · 2023 · cited 7× · PMID 36394425 · DOI 10.1111/bph.15987
Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases.
Ren J, Wang XQ, Nakao T, Libby P, et al · · 2023 · PMID 38152628 · DOI 10.1097/cd9.0000000000000096
Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study.
Küçük MP, Küçük AO, Pehlivanlar A, Mürtezaoğlu SA, et al · · 2022 · PMID 36161598 · DOI 10.3906/sag-2106-42

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other recruiting trials for Tocilizumab

Currently open trials in the same condition.

NCT04300686 — A Pilot Study in Severe Patients With Takayasu Arteritis. · Phase 4 · recruiting

Other Karadeniz Technical University trials

Trials by the same sponsor.

NCT07526779 — Motivational Interviewing on Loneliness Level, Activities of Daily Living, and Quality of Life in Elderly · NA · not yet recruiting
NCT07448168 — Effect of Standardized Patient Simulation on Nursing Students' Assessment, Diagnosis Skills, and Experiences · NA · not yet recruiting
NCT07435233 — Different Reality Simulation Education Methods on Nursing Students · NA · active not recruiting
NCT07238348 — Analgesic Effectiveness of SPSIPB Versus Thoracic Epidural and Systemic Opioid Analgesia After VATS (SPSIPB-VATS) · not yet recruiting
NCT07297498 — The Effect of Simulation-based Education Within the Framework of the Clinical Judgment Model on Nursing Students' Clinic · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04893031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karadeniz Technical University
Last refreshed: 20 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04893031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing